

# Precise Null Deletion Mutations of the Mycothiol Synthesis Genes Reveal Their Role in Isoniazid and Ethionamide Resistance in *Mycobacterium smegmatis*<sup>∇</sup>

Xia Xu,<sup>1</sup> Catherine Vilcheze,<sup>1</sup> Yossef Av-Gay,<sup>2</sup> Anaximandro Gómez-Velasco,<sup>2</sup> and William R. Jacobs, Jr.<sup>1\*</sup>

Howard Hughes Medical Institute, Department of Microbiology and Immunology, Albert Einstein College of Medicine, 1301 Morris Park Avenue, Bronx, New York 10461,<sup>1</sup> and Department of Medicine, Division of Infectious Diseases, University of British Columbia, Vancouver, British Columbia, Canada<sup>2</sup>

Received 7 January 2011/Returned for modification 31 January 2011/Accepted 6 April 2011

**Mycothiol (MSH; AcCys-GlcN-Ins) is the glutathione analogue for mycobacteria. Mutations in MSH biosynthetic genes have been associated with resistance to isoniazid (INH) and ethionamide (ETH) in mycobacteria, but rigorous genetic studies are lacking, and those that have been conducted have yielded different results. In this study, we constructed independent null deletion mutants for all four genes involved in the MSH biosynthesis pathway (*mshA*, *mshB*, *mshC*, and *mshD*) in *Mycobacterium smegmatis* and made complementing constructs in integrating plasmids. The resulting set of strains was analyzed for levels of MSH, INH resistance, and ETH resistance. The *mshA* and *mshC* single deletion mutants were devoid of MSH production and resistant to INH, whereas the *mshB* deletion mutant produced decreased levels of MSH yet was sensitive to INH, suggesting that MSH biosynthesis is essential for INH susceptibility in *M. smegmatis*. Further evidence supporting this conclusion was generated by deleting the gene encoding the MSH S-conjugate amidase (*mca*) from the  $\Delta$ *mshB* null mutant. This double mutant,  $\Delta$ *mshB*  $\Delta$ *mca*, completely abolished MSH production and was resistant to INH. The *mshA*, *mshC*, and *mshB* single deletion mutants were also resistant to ETH, indicating that ETH resistance is modulated by the level of MSH in *M. smegmatis*. Surprisingly, the *mshD* deletion mutant lacked MSH production but was sensitive to both INH and ETH. The drug sensitivity was likely mediated by the compensated synthesis of *N*-formyl-Cys-GlcN-Ins, previously demonstrated to substitute for MSH in an *mshD* mutant of *M. smegmatis*. We conclude that MSH or *N*-formyl-Cys-GlcN-Ins is required for susceptibility to INH or ETH in *M. smegmatis*.**

**Fn1/AQ:A** The molecular mechanisms of resistance to the antituberculosis drugs isoniazid (INH) and ethionamide (ETH) are not fully understood. The increasing emergence of multidrug-resistant (MDR) tuberculosis (TB) and extensively drug-resistant (XDR) TB poses a major threat to the effective control of TB globally (39), which considerably increases the need to further explore mechanisms of resistance to INH or ETH.

INH is a front-line drug which has been most widely used for the treatment of active TB and latent infection since its discovery in 1952 (5, 9). The drug enters the mycobacterial cells by passive diffusion (3). INH is a prodrug activated by the mycobacterial *katG*-encoded catalase-peroxidase (41). Mutations in *katG* cause resistance to INH in mycobacteria and are the main mechanism of INH resistance in INH-resistant clinical isolates (10, 40). *KatG*-mediated INH activation produces a range of highly reactive species such as superoxide, hydroxyl radical (28), and isonicotinic-acyl radical (38). Isonicotinic-acyl radical, the putative active form of INH, covalently binds to the nicotinamide ring of NAD, forming the isonicotinoyl-NAD (INH-NAD) adduct, which subsequently inhibits the *inhA*-encoded enoyl-acyl carrier protein (ACP) reductase (24, 25).

*InhA* is a NADH-dependent enzyme involved in the fatty acid biosynthesis type II (FASII) system, which catalyzes the reduction of the double bond at position 2 of a growing long-chain (16 or more carbon atoms) fatty acid during the fatty acid elongation process (20). Mycolic acids, whose synthesis derives from the FASII system, are important components of the outer part of the mycobacterial cell wall, where they form a hydrophobic barrier. Inhibition of *InhA* by the INH-NAD adduct in INH-treated mycobacteria leads to bacterial death through inhibition of mycolic acid biosynthesis (32, 35). Mutations within the promoter region of *inhA* confer resistance to INH by upregulating expression of target *InhA* via a drug titration mechanism (1). Resistance to INH can also be mediated by mutations in the structural region of the *inhA* gene, by lowering the *InhA* affinity to the INH-NAD adduct (25). In addition, mutations in *inhA* not only cause INH resistance, but they also confer cross-resistance to ETH, a structural analog of INH (1). ETH, a second-line antituberculosis drug most frequently used against MDR-TB (13), is also a prodrug and similar in action to INH. However, ETH requires activation by a different enzyme, the flavoprotein monooxygenase *EthA* (4, 37). Mutations in *ethA* confer resistance to ETH. *ethA* mutations have been found in both laboratory-derived and clinical ETH-resistant isolates (12).

Recently, coresistance to both INH and ETH was also observed in spontaneous mycothiol glycosyltransferase (*mshA*) mutants from *Mycobacterium tuberculosis* which produced low

\* Corresponding author. Mailing address: Albert Einstein College of Medicine, Price Center, Room 553, 1301 Morris Park Avenue, Bronx, NY 10461. Phone: (718) 678-1075. Fax: (718) 678-1085. E-mail: jacobsww@hhmi.org.

<sup>∇</sup> Published ahead of print on ●●●●●●●●.




FIG. 1. (A) MSH biosynthesis pathway. The MSH glycosyltransferase MshA links inositol-1-phosphate (Ins-P) to *N*-acetylglucosamine (GlcNAc). The product is dephosphorylated and deacetylated by the phosphatase MshA2 and the deacetylase MshB, respectively. The ligase MshC condenses cysteine and GlcN-Ins in an ATP-dependent manner, and the acetyltransferase MshD synthesizes MSH (AcCys-GlcN-Ins). CoA, coenzyme A. (B) Structure of fCys-GlcN-Ins.

levels of mycothiol (MSH; AcCys-GlcN-Ins) (34). MSH is the predominant low-molecular-weight thiol in mycobacteria, which produce no glutathione (GSH) (14). As a functional analog of GSH, MSH serves as an antioxidant thiol or detoxification agent (7, 16). Structurally different from GSH, the cysteine residue of MSH is acetylated and amide linked to disaccharide moieties composed of inositol and *N*-glucosamine (30). The MSH biosynthesis pathway in mycobacteria is illustrated in Fig. 1A (17). Except for MSH phosphatase *mshA2*, all other genes (*mshA*, MSH deacetylase *mshB*, MSH ligase *mshC*, and MSH acetyltransferase *mshD*) involved in MSH biosynthesis have been identified in mycobacteria (11, 15, 18, 27). Here, in order to clarify the underlying relationship between MSH biosynthesis and INH or ETH susceptibility in *M. smegmatis*, we precisely deleted each individual gene (*mshA*, *mshB*, *mshC*, and *mshD*) involved in the MSH biosynthesis pathway and made unmarked null deletion mutants. The deletion mutants as well as their complementary strains were assayed for MSH content and MICs of INH and ETH.

#### MATERIALS AND METHODS

**Bacterial strains and growth conditions.** *M. smegmatis* mc<sup>2</sup>155 (29) and its derived mutants were grown in 7H9 medium (Difco) supplemented with 0.05% Tween 80, 0.2% glycerol, and 10% ADS (0.081% NaCl, 0.5% bovine albumin fraction V, 0.2% dextrose). *Escherichia coli* strains DH5 $\alpha$  and HB101 were cultured with LB medium (Difco). Kanamycin (20  $\mu$ g/ml for *M. smegmatis*, 40  $\mu$ g/ml for *E. coli*) and hygromycin (100  $\mu$ g/ml for *M. smegmatis*, 150  $\mu$ g/ml for *E. coli*; Roche) were added to culture medium as needed. All chemicals used in this study were purchased from Sigma unless specified otherwise.

**Generation of gene deletion mutants.** mc<sup>2</sup>155-derived mutants were generated by allelic exchange using specialized transduction (2). DNA fragments containing ~50 bp of target gene, with ~1,000 bp of upstream and downstream flanking DNA sequence, were PCR amplified (NEB F530L, Phusion high-fidelity DNA polymerase) using the oligonucleotides listed in Table 1. The subsequent upstream and downstream arms were digested with the indicated restriction enzymes (Table 1) and cloned into Van91I-digested p0004s vector arms. P0004s is a pJSC347 (26)-derived cosmid containing lambda phage *cos* sites, a *hyg* resistance marker, and a *sacB* cassette (T. Hsu and W. R. Jacobs, Jr., unpublished data). The resulting allelic exchange substrates were digested with *PacI* and ligated with *PacI*-digested temperature-sensitive mycobacteriophage phAE159 (Hsu and Jacobs, unpublished) derived from TM4. Phage was packaged using a MaxPlax packaging extract (Epicenter Biotechnologies) for construction of shuttle phasmids in the *E. coli* HB101 strain. The obtained phasmids were electroporated into mc<sup>2</sup>155 for phage propagation. Phage was delivered into mc<sup>2</sup>155 as previously described (2). Subsequently, target genes were deleted and replaced with a  $\gamma$ *des-sacB-hyg- $\gamma$ des* cassette, using hygromycin for selection. After Hyg<sup>r</sup> selection and confirmation of the correct deletion/replacement, the  $\gamma$ *des-sacB-hyg- $\gamma$ des* cassette of the deletion/replacement allele was removed. Removal was accomplished by infection of TM4-derived phage phAE201, which expresses the  $\gamma$ *d*-resolvase enzyme (Hsu and Jacobs, unpublished), and plating on sucrose (5%, wt/vol) for counterselection. Both marked and unmarked mutants were verified by PCR and sequencing of predicted junctions. For construction of  $\Delta$ *mshB*  $\Delta$ *mca* double null deletion mutants, the *mca* gene was exchanged from the mc<sup>2</sup>155  $\Delta$ *mshB* unmarked mutant using specialized transduction, and the  $\gamma$ *des-sacB-hyg- $\gamma$ des* cassette was subsequently removed.

**Complementation of null deletion mutants.** Individual genes were amplified from mc<sup>2</sup>155 genomic DNA by PCR (Phusion high-fidelity DNA polymerase; NEB) using the oligonucleotide pairs listed in Table 2. Each individual *mshA*, *mshB*, *mshC*, or *mshD* gene was cloned into integrating plasmid pMV361 (31) using the restriction sites, underlined in Table 2. Each plasmid was sequenced to verify the presence of the wild-type gene. The resulting plasmids were transformed into null deletion mutants by electroporation, using kanamycin for selection. A representative transformant of the *M. smegmatis* mutant was verified

FI

TI

AQ: C

AQ: D

AQ: B

T2

TABLE 1. Oligonucleotides used for generation of allelic exchange substrates

Primer	Sequence	Restriction enzyme used
<i>mshA</i>		
LL	5'-TTTTTTTTCCATAAAATTGGATCTGCTCGGCCGCACGCTC-3'	Van91I
LR	5'-TTTTTTTTCCATTTCTTGGTGCGCCAGCGGAGAGGTGTG-3'	Van91I
RL	5'-TTTTTTTTGCATAGATTGCCGTTCCGGACGCCGGTTCTC-3'	BstAPI
RR	5'-TTTTTTTTGCATCTTTTGCCGGCGTCTGGCTGTAATTG-3'	BstAPI
<i>mshB</i>		
LL	5'-TTTTTTTTGCATAAAATTGCGGGCAGCACAACACCGTGAC-3'	BstAPI
LR	5'-TTTTTTTTGCATTTCTTGCCGGTGGTCAGGGTCTCGTC-3'	BstAPI
RL	5'-TTTTTTTTGCATAGATTGCGGGCCACGGGATCCCGAGG-3'	BstAPI
RR	5'-TTTTTTTTGCATCTTTTGCGCGCCTGAGTCGCTCGAGTC-3'	BstAPI
<i>mshC</i>		
LL	5'-TTTTTTTTCCATAAAATTGGATTCCGGCGGGCACCATAAC-3'	Van91I
LR	5'-TTTTTTTTCCATTTCTTGGGTCTGAAGAGGCGCAGCGCAG-3'	Van91I
RL	5'-TTTTTTTTCCATAGATTGGACGCGCTGCTACGGTGGG-3'	Van91I
RR	5'-TTTTTTTTCCATCTTTTGGTGTGCGCGCTGCTCGATCTG-3'	Van91I
<i>mshD</i>		
LL	5'-TTTTTTTTGCATAAAATTGCGCGGCTGACGAGCAGGTGAG-3'	BstAPI
LR	5'-TTTTTTTTGCATTTCTTGCTCAGCGCGGAATCTCTGCC-3'	BstAPI
RL	5'-TTTTTTTTCCATAGATTGGACCGGAAGTTGGGGTTCGAG-3'	Van91I
RR	5'-TTTTTTTTCCATCTTTTGGCGAAGCCCTTCTCGACGTAG-3'	Van91I
<i>mca</i>		
LL	5'-TTTTTTTTCCATAAAATTGGGTGATAGCCGCCGTTCTCGC-3'	Van91I
LR	5'-TTTTTTTTCCATTTCTTGGCTTGCTGGACTCGTCCG-3'	Van91I
RL	5'-TTTTTTTTCCATAGATTGGGCCGACCGAGGAGTTCGAG-3'	Van91I
RR	5'-TTTTTTTTCCATCTTTTGGTGGCGCTTGCTCTCGTACC-3'	Van91I

by PCR amplification of the integrated gene to verify successful complementation. The empty pMV361 plasmid vectors were from laboratory stock and also electroporated into null mutants as controls. The constitutive *hsp60* promoter drives cloned gene expression.

**Measurement of thiol content.** Fifty milliliters of mc<sup>2</sup>155 and its derived strains was grown to stationary phase. In triplicate, 9 ml culture was collected by centrifugation. The pellet was resuspended with 0.5 ml monobromobimane (mBBR; Biochemika) reagent (20 mM HEPES, pH 8, 2 mM mBBR, 50% acetonitrile). Samples were heated at 60°C for 15 min for thiol group labeling and then centrifuged at 6,000 rpm for 10 min. The resulting supernatant was treated with 5 M methanesulfonic acid (MSA) to stop the reaction. Samples were frozen and stored at -70°C until quantification. Fluorescence high-pressure liquid chromatography (HPLC) was performed to quantify the MSH content using standards as previously described (22). Another 9 ml culture was treated with *N*-ethylmaleimide (NEM) and then with mBBR as a control.

**Determination of MIC.** Mycobacterial cultures were grown to log phase. Ten microliters of 10-fold serial dilutions was spotted in duplicate on 7H10 agar supplemented with 0.5% dextrose, 0.5% glycerol, and INH (0, 0.5, 1, 2, 4, 8, 16, 32 µg/ml) or ETH (0, 2.5, 5, 10, 20, 40, 80, 160, 320 µg/ml). Plates were incubated at 37°C for 2 to 4 days. The lowest concentration of drug that caused a >99%

reduction in the numbers of CFU/ml compared to the number for the drug-free control was determined as the MIC.

## RESULTS

**MSH synthetic genes are nonessential for *M. smegmatis*.** In order to investigate if MSH biosynthesis influences INH or ETH susceptibility in *M. smegmatis*, we first generated independent unmarked deletion mutants of *mshA*, *mshB*, *mshC*, and *mshD* using specialized transduction (Fig. 2). For each mutated gene we obtained 20 to 50 hygromycin-resistant transductants. Three to 5 independent transductants for each gene were verified to have the deletion by PCR and sequencing. A single clone was chosen for unmarking and then stocked and used for further studies (Table 3). All four genes were successfully individually deleted from the genome of *M. smegmatis*,

TABLE 2. Oligonucleotides used for knockout complementation

Primer	Sequence	Restriction enzyme used
<i>mshA</i>	5'-GGGGGGGAATTCGTGCGTCTAGCGACAGACCT-3' 5'-GGGGGGAAGCTTTCACGTGCGTACTCCCCTGC-3'	EcoRI HindIII
<i>mshB</i>	5'-GGGGGGGAATTCATGTCATCGCATGAATCGCC-3' 5'-GGGGGGAAGCTTCTACTCCAGATCAAGCCCG-3'	EcoRI HindIII
<i>mshC</i>	5'-GGGGGGGAATTCATGCAATCGTGGTCCGACC-3' 5'-GGGGGGAAGCTTTTAGAGGTCCACACCAGCA-3'	EcoRI HindIII
<i>mshD</i>	5'-GGGGGGGAATTCGTGACCTCCACCGAGTGGC-3' 5'-GGGGGGAAGCTTGTGTTACAGGCCGAGGC-3'	EcoRI HindIII




FIG. 2. Gene deletion by specialized transduction: organization of *mshA* gene loci in *mc*<sup>2</sup>155 wild type (WT) and the  $\Delta mshA::hyg$  and  $\Delta mshA$  unmarked mutants. The central part of target genes was deleted and replaced by the  $\gamma\delta res$ -*sacB*-*hyg*- $\gamma\delta res$  cassette, which was subsequently removed utilizing the phage phAE201 expressing the  $\gamma\delta$ -resolvase. Only the first and last ~50 bp of the target gene was maintained in the genome of desired unmarked mutants.

demonstrating that *mshA*, *mshB*, *mshC*, and *mshD* genes are all nonessential in *M. smegmatis*.

In contrast to *M. tuberculosis*, *M. smegmatis* MSH biosynthetic mutants did not require catalase to grow *in vitro*. Nevertheless, we observed that on solid agar,  $\Delta mshA$  and  $\Delta mshC$  null mutants grew slightly slower than their complementary or wild-type strains (Fig. 3). However,  $\Delta mshB$  and  $\Delta mshD$  null mutants did not show significant growth defects.

**Single deletion of *mshA*, *mshC*, or *mshD* or double deletion of *mshB* and *mca* blocks MSH biosynthesis.** The MSH levels for each strain were measured by fluorescence HPLC. The  $\Delta mshA$ ,  $\Delta mshC$ , and  $\Delta mshD$  null mutants produced undetectable levels of MSH, while complemented strains regained MSH production to wild-type levels (Table 4). These results were consistent with previous reports for an *mshA* single deletion mutant from *M. tuberculosis* as well as *mshC* chemical mutant I64 from *M. smegmatis*, which contained the L205P single mutation in the *mshC* gene (22, 34). Similarly, the *M. smegmatis mshD::Tn5* mutant and *M. tuberculosis mshD* single deletion mutant were previously reported to produce very low levels of MSH, which varied from less than 1% to 3% of the wild-type level of MSH, depending on the growth phase (6, 11). However, the  $\Delta mshB$  mutant still produced about 20% MSH (Table 4), consistent with previously published data for *mshB* mutants from both *M. tuberculosis* and *M. smegmatis* (7, 21).

The *mshB* gene has a homologous gene in *M. smegmatis* named *mca* that encodes the MSH S-conjugate amidase which exhibits low *N*-acetylglucosaminylinositol (GlcNAc-Ins) deacetylation activity (15, 16). In this study, for the first time, the *mca* gene was deleted from the genome of the  $\Delta mshB$  null mutant by specialized transduction, and the replacement antibiotic cassette was subsequently removed by site-specific excision (see Materials and Methods). The *M. smegmatis*  $\Delta mshB \Delta mca$  double null deletion mutant produced no detectable MSH (Table 4). Complementation with *M. smegmatis mshB* restored MSH biosynthesis. Interestingly, the  $\Delta mca$  single null deletion mutant showed increased MSH levels (Table 4).

***M. smegmatis* MSH biosynthesis mutants have various sensitivities to INH or ETH.** The MICs against INH were determined using the proportion method (see Materials and Methods), and a  $\geq 4$ -fold change was considered significant and resistant. The  $\Delta mshA$  and  $\Delta mshC$  null mutants displayed 4- to 8-fold higher MICs than the wild-type strain for INH. In contrast, the MICs of INH for the  $\Delta mshB$  and  $\Delta mshD$  null mutants had no significant change (Table 4). Complementation with the *M. smegmatis mshA* or *mshC* gene restored INH susceptibility to the wild-type level (Table 4). The MIC results for INH for our MSH mutants are consistent with those published for an *mshB* mutant from *M. tuberculosis* or *M. smegmatis* and *M. smegmatis mshC* chemical mutant I64 (7, 21, 22).

TABLE 3. Strains used in this study

Strain	Relevant genotype	Plasmid	How constructed
<i>mc</i> <sup>2</sup> 155	Wild type	None	As described previously (29)
<i>mc</i> <sup>2</sup> 7077	$\Delta mshA$ (MSMEG_0933)	None	Specialized transduction of <i>mc</i> <sup>2</sup> 155
<i>mc</i> <sup>2</sup> 7083	$\Delta mshA$ pMV361:: <i>mshA</i>	pMV361- <i>mshA</i>	Transformation of <i>mc</i> <sup>2</sup> 7077
<i>mc</i> <sup>2</sup> 7078	$\Delta mshB$ (MSMEG_5129)	None	Specialized transduction of <i>mc</i> <sup>2</sup> 155
<i>mc</i> <sup>2</sup> 7085	$\Delta mshB$ pMV361:: <i>mshB</i>	pMV361- <i>mshB</i>	Transformation of <i>mc</i> <sup>2</sup> 7078
<i>mc</i> <sup>2</sup> 7079	$\Delta mshC$ (MSMEG_4189)	None	Specialized transduction of <i>mc</i> <sup>2</sup> 155
<i>mc</i> <sup>2</sup> 7087	$\Delta mshC$ pMV361:: <i>mshC</i>	pMV361- <i>mshC</i>	Transformation of <i>mc</i> <sup>2</sup> 7079
<i>mc</i> <sup>2</sup> 7080	$\Delta mshD$ (MSMEG_5783)	None	Specialized transduction of <i>mc</i> <sup>2</sup> 155
<i>mc</i> <sup>2</sup> 7089	$\Delta mshD$ pMV361:: <i>mshD</i>	pMV361- <i>mshD</i>	Transformation of <i>mc</i> <sup>2</sup> 7080
<i>mc</i> <sup>2</sup> 7081	$\Delta mca$ (MSMEG_5261)	None	Specialized transduction of <i>mc</i> <sup>2</sup> 155
<i>mc</i> <sup>2</sup> 7082	$\Delta mshB \Delta mca$	None	Specialized transduction of <i>mc</i> <sup>2</sup> 7078
<i>mc</i> <sup>2</sup> 7152	$\Delta mshB \Delta mca$ pMV361:: <i>mshB</i>	pMV361- <i>mshB</i>	Transformation of <i>mc</i> <sup>2</sup> 7082




FIG. 3. Growth defect of  $\Delta mshA$  or  $\Delta mshC$  null mutant on solid agar. The same amount of bacteria with 10-fold serial dilutions was spotted on 7H10 agar supplemented with 0.5% dextrose and 0.5% glycerol. The plates were incubated at 37°C for 24, 48, and 72 h. c, complementation.

In *M. tuberculosis*, *mshA* mutants were also shown to be resistant to ETH (34). Therefore, we also measured MICs of ETH for all strains. Like *M. tuberculosis mshA* spontaneous mutants (35), *M. smegmatis*  $\Delta mshA$ ,  $\Delta mshB$ , and  $\Delta mshC$  had 8-fold higher MICs for ETH. Complementation with *M. smegmatis mshA*, *mshB*, or *mshC* restored ETH susceptibility to that of the wild type (Table 4). Interestingly, the MIC of ETH for  $\Delta mshD$  was identical to that of the wild type (Table 4).

The MICs of both INH and ETH for the  $\Delta mshB$   $\Delta mca$  double mutant were 8-fold higher than those for the wild type (Table 4). Complementation with the *M. smegmatis mshB* gene restored susceptibility for both INH and ETH (Table 4). The  $\Delta mca$  single deletion mutant had MICs for both INH and ETH identical to those of the wild type (Table 4), which was consistent with a previous report (23). The pMV361 control transformants of all null mutants yielded INH and ETH MICs identical to those of the parental strains, as expected (data not shown).

## DISCUSSION

Our ability to successfully delete each of the 4 genes involved in MSH biosynthesis in *M. smegmatis* clearly shows that none of the MSH biosynthetic genes is essential for this organism under *in vitro* growth conditions. Unlike *M. tuberculosis*  $\Delta mshA$  and  $\Delta mshD$ , which require exogenous catalase to grow *in vitro* (6, 34), the *M. smegmatis* MSH synthetic mutants in this study grew on solid plate or liquid medium without catalase. One possible explanation might rely on the difference in the redox balance between the two microorganisms (33).

Our MSH synthetic mutants demonstrated that deletion of *mshA*, *mshC*, or *mshD* is sufficient to block MSH production in *M. smegmatis*. However,  $\Delta mshB$  null mutants retained significant MSH biosynthesis. It was proposed previously that *mca* could partially compensate for the MSH biosynthesis pathway when *mshB* is deleted in *M. smegmatis* (21). We confirmed the hypothesis by demonstrating that deletion of both *mca* and *mshB* resulted in the complete inhibition of MSH biosynthesis in *M. smegmatis*. The *mca* gene is conserved between *M. smegmatis* and *M. tuberculosis*; therefore, it is plausible that deletion of both *mca* and *mshB* would also deplete MSH production in

*M. tuberculosis*. *Mca* has deacetylation activity on GlcNAc-Ins and is also an MSH-dependent detoxification protein. *Mca* hydrolyzes an amide bond in the MSH-toxin conjugates, producing a mercapturic acid of the toxin which is excreted from the bacteria. The remaining product, GlcN-Ins, is reutilized as a substrate of MshC for the recycling of MSH biosynthesis (16). Our *M. smegmatis*  $\Delta mca$  null mutant had an increased MSH level, supporting the suggestion that the main function of *Mca* is normally not MSH biosynthesis but, rather, the MSH-dependent detoxification pathway. Compared to the amidase activity on an mBBr derivative of MSH (MSmB), *Mca* has low activity on MSH (4 versus 4,480 nmol min<sup>-1</sup> mg<sup>-1</sup>) (16). *Mca* was proposed to be involved in the degradation of MSH (8), and the increase of the MSH level in our *M. smegmatis*  $\Delta mca$  null mutant could be partially caused by the blockage of the degradation of MSH.

The  $\Delta mshA$  and  $\Delta mshC$  single mutants did not produce MSH and were shown to be resistant to INH, whereas the  $\Delta mshB$  mutant, which still produced 20% MSH, was sensitive to INH, suggesting that the lack of MSH confers INH resistance in *M. smegmatis*. In order to further test this hypothesis, the MIC of INH was also determined for our *M. smegmatis*  $\Delta mshB$   $\Delta mca$  double mutant, which completely lacks MSH production. As we expected, the double mutant  $\Delta mshB$   $\Delta mca$  was resistant to INH. In contrast,  $\Delta mshA$  conferred resistance to ETH but not to INH in *M. tuberculosis* (34). Similarly to INH, MSH-deficient mutants, such as the  $\Delta mshA$  or  $\Delta mshC$  null mutant, were resistant to ETH. Interestingly, *M. smegmatis*  $\Delta mshB$  was also resistant to ETH, indicating that ETH susceptibility is modulated by the MSH level in *M. smegmatis*.

Surprisingly, *M. smegmatis*  $\Delta mshD$  lacked MSH but was sensitive to both INH and ETH. MshD is the MSH synthase and catalyzes N-acetylation of Cys-GlcN-Ins to produce MSH in the final step of MSH biosynthesis (11). In the *M. smegmatis* *mshD::Tn5* mutant or  $\Delta mshD$  null mutant from *M. tuberculosis*, the most abundant reduced form of thiol is a novel thiol *N*-formyl-Cys-GlcN-Ins (fCys-GlcN-Ins) (Fig. 1B), a derivative of Cys-GlcN-Ins (6, 19). However, the substrate Cys-GlcN-Ins that accumulated in the *mshD* mutants is substantially oxidized (6, 19). Although fCys-GlcN-Ins and Cys-GlcN-Ins are the two most abundant thiols in the *mshD* mutant, the MSH-dependen-

TABLE 4. MICs for INH/ETH and MSH concentration

<i>M. smegmatis</i> strain	MIC (μg/ml)		MSH concn (nmol/10 <sup>9</sup> cells)
	INH	ETH	
mc <sup>2</sup> 155	4	20	13 ± 5
$\Delta mshA$	32	160	<0.05
$\Delta mshA$ pMV361:: <i>mshA</i>	4	20	16 ± 5
$\Delta mshB$	8	160	3.2 ± 1.5
$\Delta mshB$ pMV361:: <i>mshB</i>	4	20	10 ± 4
$\Delta mshC$	16	160	<0.05
$\Delta mshC$ pMV361:: <i>mshC</i>	4	20	12 ± 1
$\Delta mshD^a$	4	20	<0.05
$\Delta mshD$ pMV361:: <i>mshD</i>	4	20	12 ± 1
$\Delta mca$	4	20	44 ± 0.02
$\Delta mshB$ $\Delta mca$	32	160	<0.05
$\Delta mshB$ $\Delta mca$ pMV361:: <i>mshB</i>	4	20	27 ± 2

<sup>a</sup> The quantification of fCys-GlcN-Ins and Cys-GlcN-Ins was estimated by using MSmB and Cys-mB as standards, respectively. fCys-GlcN-Ins, (1.4 ± 0.1) nmol/10<sup>9</sup> cells; Cys-GlcN-Ins, (1.8 ± 0.7) nmol/10<sup>9</sup> cells.




FIG. 4. Formation of fCySmB-GlcN-Ins in *M. smegmatis*  $\Delta mshD$  null deletion mutant. The cells were pelleted and labeled with 2 mM fluorescence reagent mBBr (20 mM HEPES, pH 8, 50% acetonitrile) and then heated at 60°C for 15 min and spun. MSA (5 M) was added into the supernatant to stop the label reaction, and thiols were analyzed by fluorescence HPLC. P1, CySmB-GlcN-Ins, the bimane derivative of Cys-GlcN-Ins; P2, fCySmB-GlcN-Ins, the bimane derivative of fCys-GlcN-Ins, MSmB, the MSH bimane.

dent enzymes Mca and mycothiol reductase (Mtr) have better activity on the bimane derivative of fCys-GlcN-Ins (fCySmB-GlcN-Ins) and disulfide of fCys-GlcN-Ins than on the bimane derivative of Cys-GlcN-Ins (CySmB-GlcN-Ins) and disulfide of Cys-GlcN-Ins (50-fold and  $\geq 3$ -fold higher, respectively), indicating that fCys-GlcN-Ins is a better substitute for MSH than Cys-GlcN-Ins (19). Lack of MSH is associated with hypersensitivity to oxidant or alkylating agents. However, *M. smegmatis*  $mshD::Tn5$  exhibited no enhanced sensitivity to peroxides compared to the parental strain, supporting the suggestion that fCys-GlcN-Ins functions as an alternative for MSH in the *M. smegmatis*  $mshD::Tn5$  mutant (19). In our *M. smegmatis*  $\Delta mshD$  null mutant, a specific extra peak (P2) eluting right before the MSH bimane (MSmB) was observed during the determination of the MSH content (Fig. 4). This specific peak was absent in the complementary strain and wild type (Fig. 4), suggesting that P2 represented the formation of fCySmB-GlcN-Ins. The P2 fraction was collected for analysis using Fourier transform ion cyclotron resonance mass spectrometry (FTICR-MS). We detected a peak showing a monoisotopic mass-to-charge ratio ( $m/z$ ) of 685.1995, which is close to the calculated  $m/z$  of 685.1997 for (fCySmB-GlcN-Ins + Na)<sup>+</sup>, demonstrating that P2 is fCySmB-GlcN-Ins. Therefore, we reasoned that the sensitivity to both INH and ETH in our *M.*

*smegmatis*  $\Delta mshD$  null mutant could also be caused by the formation of fCys-GlcN-Ins, an analog of MSH.

Mechanisms for INH or ETH resistance in *M. smegmatis* MSH biosynthetic mutants remain unanswered. Since previous studies has shown that coresistance to both INH and ETH in *M. smegmatis* and *M. bovis* mutants was linked to mutations in the *ndh*-encoded type II NADH dehydrogenase (NdhII) (36) due to the increased intracellular NADH level, we measured the NADH concentration in our mutants. None of our INH/ETH-resistant  $\Delta mshA$ ,  $\Delta mshB$ ,  $\Delta mshC$ , and  $\Delta mshB \Delta mca$  null mutants had an increased level of NADH (data not shown). Furthermore, our *M. smegmatis*  $\Delta mshB$  null deletion mutant reveals an intriguing difference from the *mshA* and *mshC* single deletion mutants, as its resistance only to ETH indicates that MSH may not be involved in the common pathway of INH and ETH action. Therefore, we hypothesize that MSH must be involved in the activation of INH and ETH. *In vitro*, MSH was shown to slightly enhance the activity of *M. tuberculosis* EthA, suggesting that MSH is involved in the ETH activation step in *M. tuberculosis* (34). Our *M. smegmatis* MSH mutants confirmed the role of MSH in ETH susceptibility. In contrast to our *M. smegmatis*  $mshA$  deletion mutant, the *M. tuberculosis*  $\Delta mshA$  mutant was sensitive to INH (34). We speculate that MSH also plays a role in the activation of INH by KatG, but

since *M. tuberculosis* KatG is more efficient to activate INH than *M. smegmatis* KatG, the lack of MSH biosynthesis has no effect on INH susceptibility in TB. In contrast, in *M. smegmatis*, with a less efficient activation of the drug, inhibition of MSH biosynthesis results in a 4- to 8-fold increase in INH resistance.

The main finding of this study is the demonstration of the essentiality of MSH for INH or ETH susceptibility in *M. smegmatis*. The exception in the case of  $\Delta mshD$  is probably caused by the availability of an alternative reducing molecule, fCys-GlcN-Ins. With the increasing use of ETH in the treatment of XDR-TB, screening for mutations in *mshA*, *mshB*, and *mshC* for clinical *M. tuberculosis* isolates is merited. This knowledge would facilitate the development of new diagnostics for ETH resistance using DNA analysis methodologies.

#### ACKNOWLEDGMENTS

We thank Derek Smith and Jun Han at the UVic-Genome BC Proteomics Centre for their assistance in the mass spectrometry sample analysis. We are grateful to David Thaler for helpful comments on the manuscript.

We acknowledge support for this work from NIH grant AI26170 and the CFAR grant AI051519. Research at the Y. Av-Gay Laboratory was supported by a British Columbia Lung Association operating grant.

#### REFERENCES

AQ: E

- Banerjee, A., et al. 1994. *inhA*, a gene encoding a target for isoniazid and ethionamide in *Mycobacterium tuberculosis*. *Science* **263**:227–230.
- Bardarov, S., et al. 2002. Specialized transduction: an efficient method for generating marked and unmarked targeted gene disruptions in *Mycobacterium tuberculosis*, *M. bovis* BCG and *M. smegmatis*. *Microbiology* **148**:3007–3017.
- Bardou, F., C. Raynaud, C. Ramos, M. A. Laneelle, and G. Laneelle. 1998. Mechanism of isoniazid uptake in *Mycobacterium tuberculosis*. *Microbiology* **144**(Pt 9):2539–2544.
- Baulard, A. R., et al. 2000. Activation of the pro-drug ethionamide is regulated in mycobacteria. *J. Biol. Chem.* **275**:28326–28331.
- Bernstein, J., W. A. Lott, B. A. Steinberg, and H. L. Yale. 1952. Chemotherapy of experimental tuberculosis. V. Isonicotinic acid hydrazide (nydrazid) and related compounds. *Am. Rev. Tuberc.* **65**:357–364.
- Buchmeier, N. A., G. L. Newton, and R. C. Fahey. 2006. A mycothiol synthase mutant of *Mycobacterium tuberculosis* has an altered thiol-disulfide content and limited tolerance to stress. *J. Bacteriol.* **188**:6245–6252.
- Buchmeier, N. A., G. L. Newton, T. Koledin, and R. C. Fahey. 2003. Association of mycothiol with protection of *Mycobacterium tuberculosis* from toxic oxidants and antibiotics. *Mol. Microbiol.* **47**:1723–1732.
- Bzymek, K. P., G. L. Newton, P. Ta, and R. C. Fahey. 2007. Mycothiol import by *Mycobacterium smegmatis* and function as a resource for metabolic precursors and energy production. *J. Bacteriol.* **189**:6796–6805.
- Fox, H. H. 1952. The chemical approach to the control of tuberculosis. *Science* **116**:129–134.
- Hazbon, M. H., et al. 2006. Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant *Mycobacterium tuberculosis*. *Antimicrob. Agents Chemother.* **50**:2640–2649.
- Koledin, T., G. L. Newton, and R. C. Fahey. 2002. Identification of the mycothiol synthase gene (*mshD*) encoding the acetyltransferase producing mycothiol in actinomycetes. *Arch. Microbiol.* **178**:331–337.
- Morlock, G. P., B. Metchock, D. Sikes, J. T. Crawford, and R. C. Cooksey. 2003. *ethA*, *inhA*, and *katG* loci of ethionamide-resistant clinical *Mycobacterium tuberculosis* isolates. *Antimicrob. Agents Chemother.* **47**:3799–3805.
- Mukherjee, J. S., et al. 2004. Programmes and principles in treatment of multidrug-resistant tuberculosis. *Lancet* **363**:474–481.
- Newton, G. L., et al. 1996. Distribution of thiols in microorganisms: mycothiol is a major thiol in most actinomycetes. *J. Bacteriol.* **178**:1990–1995.
- Newton, G. L., Y. Av-Gay, and R. C. Fahey. 2000. N-Acetyl-L-D-myo-inosityl-2-amino-2-deoxy- $\alpha$ -D-glucopyranoside deacetylase (*MshB*) is a key enzyme in mycothiol biosynthesis. *J. Bacteriol.* **182**:6958–6963.
- Newton, G. L., Y. Av-Gay, and R. C. Fahey. 2000. A novel mycothiol-dependent detoxification pathway in mycobacteria involving mycothiol S-conjugate amidase. *Biochemistry* **39**:10739–10746.
- Newton, G. L., N. Buchmeier, and R. C. Fahey. 2008. Biosynthesis and functions of mycothiol, the unique protective thiol of actinobacteria. *Microbiol. Mol. Biol. Rev.* **72**:471–494.
- Newton, G. L., et al. 2003. The glycosyltransferase gene encoding the enzyme catalyzing the first step of mycothiol biosynthesis (*mshA*). *J. Bacteriol.* **185**:3476–3479.
- Newton, G. L., P. Ta, and R. C. Fahey. 2005. A mycothiol synthase mutant of *Mycobacterium smegmatis* produces novel thiols and has an altered thiol redox status. *J. Bacteriol.* **187**:7309–7316.
- Quemard, A., et al. 1995. Enzymatic characterization of the target for isoniazid in *Mycobacterium tuberculosis*. *Biochemistry* **34**:8235–8241.
- Rawat, M., S. Kovacevic, H. Billman-Jacobe, and Y. Av-Gay. 2003. Inactivation of *mshB*, a key gene in the mycothiol biosynthesis pathway in *Mycobacterium smegmatis*. *Microbiology* **149**:1341–1349.
- Rawat, M., et al. 2002. Mycothiol-deficient *Mycobacterium smegmatis* mutants are hypersensitive to alkylating agents, free radicals, and antibiotics. *Antimicrob. Agents Chemother.* **46**:3348–3355.
- Rawat, M., et al. 2004. Targeted mutagenesis of the *Mycobacterium smegmatis* *mca* gene, encoding a mycothiol-dependent detoxification protein. *J. Bacteriol.* **186**:6050–6058.
- Rawat, R., A. Whitty, and P. J. Tonge. 2003. The isoniazid-NAD adduct is a slow, tight-binding inhibitor of *InhA*, the *Mycobacterium tuberculosis* enoyl reductase: adduct affinity and drug resistance. *Proc. Natl. Acad. Sci. U. S. A.* **100**:13881–13886.
- Rozwarski, D. A., G. A. Grant, D. H. Barton, W. R. Jacobs, Jr., and J. C. Sacchettini. 1998. Modification of the NADH of the isoniazid target (*InhA*) from *Mycobacterium tuberculosis*. *Science* **279**:98–102.
- Sambandanmuthy, V. K., et al. 2002. A pantothenate auxotroph of *Mycobacterium tuberculosis* is highly attenuated and protects mice against tuberculosis. *Nat. Med.* **8**:1171–1174.
- Sareen, D., M. Steffek, G. L. Newton, and R. C. Fahey. 2002. ATP-dependent L-cysteine:1D-myo-inosityl 2-amino-2-deoxy- $\alpha$ -D-glucopyranoside ligase, mycothiol biosynthesis enzyme *MshC*, is related to class I cysteinyl-tRNA synthetases. *Biochemistry* **41**:6885–6890.
- Shoeb, H. A., B. U. Bowman, Jr., A. C. Ottolenghi, and A. J. Merola. 1985. Peroxidase-mediated oxidation of isoniazid. *Antimicrob. Agents Chemother.* **27**:399–403.
- Snapper, S. B., R. E. Melton, S. Mustafa, T. Kieser, and W. R. Jacobs, Jr. 1990. Isolation and characterization of efficient plasmid transformation mutants of *Mycobacterium smegmatis*. *Mol. Microbiol.* **4**:1911–1919.
- Spies, H. S., and D. J. Steenkamp. 1994. Thiols of intracellular pathogens. Identification of ovoidin A in *Leishmania donovani* and structural analysis of a novel thiol from *Mycobacterium bovis*. *Eur. J. Biochem.* **224**:203–213.
- Stover, C. K., et al. 1991. New use of BCG for recombinant vaccines. *Nature* **351**:456–460.
- Takayama, K., L. Wang, and H. L. David. 1972. Effect of isoniazid on the in vivo mycolic acid synthesis, cell growth, and viability of *Mycobacterium tuberculosis*. *Antimicrob. Agents Chemother.* **2**:29–35.
- Ung, K. S., and Y. Av-Gay. 2006. Mycothiol-dependent mycobacterial response to oxidative stress. *FEBS Lett.* **580**:2712–2716.
- Vilcheze, C., et al. 2008. Mycothiol biosynthesis is essential for ethionamide susceptibility in *Mycobacterium tuberculosis*. *Mol. Microbiol.* **69**:1316–1329.
- Vilcheze, C., et al. 2000. Inactivation of the *inhA*-encoded fatty acid synthase II (*FASII*) enoyl-acyl carrier protein reductase induces accumulation of the *FASII* end products and cell lysis of *Mycobacterium smegmatis*. *J. Bacteriol.* **182**:4059–4067.
- Vilcheze, C., et al. 2005. Altered NADH/NAD<sup>+</sup> ratio mediates coresistance to isoniazid and ethionamide in mycobacteria. *Antimicrob. Agents Chemother.* **49**:708–720.
- Wang, F., et al. 2007. Mechanism of thioamide drug action against tuberculosis and leprosy. *J. Exp. Med.* **204**:73–78.
- Wilming, M., and K. Johnsson. 1999. Spontaneous formation of the bioactive form of the tuberculosis drug isoniazid. *Angew. Chem. Int. ed. Engl.* **38**:2588–2590.
- World Health Organization. 2009. Epidemiology. In *Global tuberculosis control—epidemiology, strategy, financing*. World Health Organization, Geneva, Switzerland. [http://www.who.int/tb/publications/global\\_report/2009/pdf/chapter1.pdf](http://www.who.int/tb/publications/global_report/2009/pdf/chapter1.pdf).
- Zhang, Y., T. Garbe, and D. Young. 1993. Transformation with *katG* restores isoniazid-sensitivity in *Mycobacterium tuberculosis* isolates resistant to a range of drug concentrations. *Mol. Microbiol.* **8**:521–524.
- Zhang, Y., B. Heym, B. Allen, D. Young, and S. Cole. 1992. The catalase-peroxidase gene and isoniazid resistance of *Mycobacterium tuberculosis*. *Nature* **358**:591–593.